Drug Profile

Cetoquagene parvec - MeiraGTx

Alternative Names: AAV-hAQP1; A00X; AAV-AQP1; AAV2-hAQP1; Cetoquagene Parvec

Latest Information Update: 24 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kadmon Gene Therapy Holdings
Developer MeiraGTx
Class Gene therapies
Mechanism of Action Aquaporin 1 replacements; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Xerostomia
New Molecular Entity No

Highest Development Phases

Phase III Xerostomia
Phase I/II Sjogren's syndrome

Most Recent Events

13 Aug 2026 MeiraGTx plans to file biological license application (BLA) for Xerostomia in mid-2027
10 Aug 2026 MeiraGTx completes a phase I trial in Xerostomia in USA (Parenteral) (NCT02446249)
30 Jun 2026 MeiraGTx completes enrolment in the phase II AQUAx2 trial for Xerostomia in USA, Canada and United Kingdom (Intraglandular) (NCT05926765)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com